Tislelizumab manufacturers
- Tislelizumab
-
- $98.00
-
2026-05-21
- CAS:1858168-59-8
- Purity: 95.07%
- Supply Ability: 10g
|
| | Tislelizumab Basic information |
| Product Name: | Tislelizumab | | Synonyms: | Tislelizumab;Research Grade Tislelizumab(DHH02206);Research Grade Tislelizumab;Tislelizumab (anti-PDCD1);Immunoglobulin G4, anti-(human programmed cell death protein 1) synthetic clone 317-4B6 heavy chain VH fragment fusion protein with human γ4 chain clone mut10 effector/constant domain fragment, disulfide with anti-(human programmed cell death protein 1) synthetic clone 317-4B6 light chain VL fragment fusion protein with human κ chain constant region fragment, dimer (ACI) | | CAS: | 1858168-59-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tislelizumab Structure]() |
| | Tislelizumab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | Tislelizumab Usage And Synthesis |
| Uses | Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma[1][2][3]. | | in vivo | Tislelizumab (10 mg/kg; Intraperitoneal injection; Once a week; 4 weeks) has significant antitumor effect in the B16F10 melanoma mouse model[2]. | Animal Model: | B16F10/GM-CSF tumor cells treated hPD-1 C57BL/6 transgenic mice[2] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.); once a week for 4 weeks. | | Result: | Exerted remarkable antitumor efficacy, resulting in approximate 86.7% tumor growth inhibition. |
| | References | [1] Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717. DOI:10.1001/jamaoncol.2021.0366
[2] Hong Y, et al. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021 Mar;11(3):782-792. DOI:10.1002/2211-5463.13102
[3] Zhu K, et al. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Front Pharmacol. 2024 Feb 22;15:1355081. DOI:10.3389/fphar.2024.1355081 |
| | Tislelizumab Preparation Products And Raw materials |
|